Athersys to Present at 2013 Stem Cell Meeting on the Mesa

Athersys to Present at 2013 Stem Cell Meeting on the Mesa

CLEVELAND, Oct. 7, 2013 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX)
announced today that Gil Van Bokkelen, Chairman and CEO of Athersys, will
present at the 3^rd Annual Regenerative Medicine (Regen Med) Partnering Forum,
part of the Stem Cell Meeting on the Mesa to be held October 14-16 in La
Jolla, CA.

Organized by the Alliance for Regenerative Medicine (ARM), the California
Institute for Regenerative Medicine (CIRM) and the Sanford Consortium for
Regenerative Medicine, the 2013 Stem Cell Meeting on the Mesa is a three-day
conference aimed at bringing together senior members of the regenerative
medicine industry with the scientific research community to advance stem cell
science into more effective treatments and potential cures for serious medical
conditions where current standard of care does not adequately address patient
needs. The Regen Med Partnering Forum, held October 14 & 15 at the Estancia La
Jolla Hotel, is the only partnering meeting organized specifically for the
regenerative medicine and advanced therapies industry.

The meeting also features a nationally recognized Scientific Symposium, held
October 16 at the Salk Institute for Biological Studies, showcasing leading
academic research in the field of regenerative medicine. Combined, these
meetings attract over 800 attendees from around the globe, fostering key
partnerships through one-on-one meetings, while also highlighting clinical and
commercial progress in the field.

The following are specific details regarding Athersys' presentation at the

Event:     Regen Med Partnering Forum – 2013 Stem Cell Meeting on the Mesa
Date:     October 15, 2013
Time:     11:00 a.m. Pacific Time
Location: Estancia La Jolla Hotel & Spa, 9700 North Torrey Pines Road,
          La Jolla, CA 92037

A live video webcast of all company presentations will be available at: and will also be published on
ARM's website shortly after the event.

Please visit for full information
including registration. Complimentary attendance at this event is available
for credentialed investors and members of the media only. Investors and media
should contact Laura Parsons at

About Athersys

Athersys is a clinical stage biotechnology company engaged in the discovery
and development of therapeutic product candidates designed to extend and
enhance the quality of human life. The Company is developing its MultiStem
cell therapy product, a patented, adult-derived "off-the-shelf" regenerative
medicine therapy for disease indications in the cardiovascular, neurological,
inflammatory and immune disease areas. The Company currently has several
clinical stage programs involving MultiStem, including for treating
inflammatory bowel disease, ischemic stroke, damage caused by myocardial
infarction, and for the prevention of graft versus host disease. Athersys has
also developed a diverse portfolio that includes other technologies and
product development opportunities, and has forged strategic partnerships and
collaborations with leading pharmaceutical and biotechnology companies, as
well as world-renowned research institutions in the United States and Europe
to further develop its platform and products. More information is available at The Athersys, Inc. logo is available at:

CONTACT: William (B.J.) Lehmann, J.D.
         President and Chief Operating Officer
         Tel: (216) 431-9900
         Investor Relations:
         Lisa M. Wilson
         In-Site Communications
         Tel: (917) 543-9932

company logo
Press spacebar to pause and continue. Press esc to stop.